Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scient...
February 01 2021 - 4:05PM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, announced today the appointment of Rob Schott, MD, MPH,
FACC, as Senior Vice President and Head of Development. Dr. Schott
will lead clinical strategy across all phases of development and
regulatory approval and will report to Sandy Macrae, Sangamo’s
Chief Executive Officer. Sangamo also announced today that,
effective January 1, 2021, Jason Fontenot, PhD, has been promoted
to Chief Scientific Officer. Dr. Fontenot has served as Sangamo’s
Head of Cell Therapy since March 2019 and as the acting Interim
Head of Research since June 2020.
“I am delighted to welcome Rob to Sangamo at this important time
when we expect a steady flow of data readouts from our ongoing
clinical trials and are focused on clinical execution,” said Dr.
Macrae. “Rob’s leadership capabilities and drug development
experience will help Sangamo advance our late-stage pipeline and
prioritize our development efforts on programs with the highest
likelihood to produce best- or first-in-class products.”
Prior to joining Sangamo, Dr. Schott served as the Chief Medical
Officer at Chorus, an autonomous early-phase development engine
inside of Eli Lilly, where he oversaw teams working to expand Eli
Lilly’s pipeline. Earlier in his career, Dr. Schott served as
Cardiovascular Department Chair and Vice President of Medical
Affairs at Sutter Medical Center Sacramento while continuing to
care for patients as an invasive cardiologist. Dr. Schott received
his undergraduate and medical degrees from the University of
Michigan. He trained in cardiovascular medicine at the
Massachusetts General Hospital after working as a post-doctoral
fellow at the Harvard Medical School.
“Jason has contributed significantly to Sangamo with his wealth
of experience in Tregs, lymphocyte biology, cell engineering and
immune-mediated disease. This new role enables Jason to continue
building upon our heritage in genomic and cellular science. Jason
and the Research team will be essential partners to Rob and the
Development team in advancing our differentiated technology to
support a robust clinical pipeline,” Dr. Macrae said.
In June 2020, Sangamo announced its decision to separate
research and development into discrete functions to increase the
speed and efficiency of translating ground-breaking science into
genomic medicine.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, cell therapy, and genome
engineering. For more information about Sangamo, visit
www.sangamo.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to the potential
to develop, obtain regulatory approvals for and commercialize
therapies to treat genetic diseases and the timing thereof,
anticipated plans and timelines of Sangamo and its collaborators
for conducting clinical trials and sharing clinical data and other
statements that are not historical fact. These statements are not
guarantees of future performance and are subject to certain risks
and uncertainties that are difficult to predict. Sangamo’s actual
results may differ materially and adversely from those expressed.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the evolving
COVID-19 pandemic and its impact on the global business
environment, healthcare systems and the business and operations of
Sangamo and its collaborators; and the uncertain timing of clinical
trials. These risks and uncertainties are described more fully in
Sangamo's Securities and Exchange Commission filings and reports,
including in Sangamo’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2020. Forward-looking statements
contained in this announcement are made as of this date, and
Sangamo undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210201005787/en/
Investor Relations & Media
Inquiries Aron Feingold 628.252.7494
afeingold@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024